WorldCare Clinical Promotes Richard Walovitch, Ph.D., to President
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
"The promotion of Richard to president is a reflection of his many contributions to WorldCare Clinical's success in expanding the breadth and depth of our service offerings," said Managing Director Michael O'Brien. "Rick's years of experience and scientific contributions in the area of medical imaging assessment strategies and processes in clinical research have allowed our company to deliver high quality services to our clients in a timely and efficient manner. Under Rick's leadership, WCC is setting new standards of performance testing and training in the critical area of reader reliability, as well as delivering quality and efficiency improvement approaches to end point assessment committee processes."
As president, Dr. Walovitch will continue to provide medical leadership for the entire organization. Additionally he is responsible for directing the operations, regulatory, sales and marketing activities and plays a vital role in defining the strategic vision of the company.
Dr. Walovitch joined WCC in January 2009 as chief medical officer. He previously served as senior vice president of clinical research at Acusphere, Inc., where he was responsible for the development and implementation of worldwide clinical strategies for product opportunities in multiple therapeutic areas, including cardiology imaging, oncology, pulmonology, and analgesia. Prior to Acusphere, he served as vice president of preclinical and clinical research at Epix Medical, which included supervision of Phase I and II clinical trials for an MRI angiography agent, and held various positions as research pharmacologist and project clinician in the Imaging Agent Group at the DuPont Merck Pharmaceutical Company. He completed his postdoctoral fellowship at the National Institute on Drug Abuse's Addiction Research Center in the Neurochemistry section. Dr. Walovitch has a doctorate in pharmacology from the University of Illinois Medical Center and a bachelor's degree in biology from the University of Illinois. He is an author of more than 100 peer-reviewed publications, mostly in the field of medical imaging.
As president, Dr. Walovitch will continue to provide medical leadership for the entire organization. Additionally he is responsible for directing the operations, regulatory, sales and marketing activities and plays a vital role in defining the strategic vision of the company.
Dr. Walovitch joined WCC in January 2009 as chief medical officer. He previously served as senior vice president of clinical research at Acusphere, Inc., where he was responsible for the development and implementation of worldwide clinical strategies for product opportunities in multiple therapeutic areas, including cardiology imaging, oncology, pulmonology, and analgesia. Prior to Acusphere, he served as vice president of preclinical and clinical research at Epix Medical, which included supervision of Phase I and II clinical trials for an MRI angiography agent, and held various positions as research pharmacologist and project clinician in the Imaging Agent Group at the DuPont Merck Pharmaceutical Company. He completed his postdoctoral fellowship at the National Institute on Drug Abuse's Addiction Research Center in the Neurochemistry section. Dr. Walovitch has a doctorate in pharmacology from the University of Illinois Medical Center and a bachelor's degree in biology from the University of Illinois. He is an author of more than 100 peer-reviewed publications, mostly in the field of medical imaging.
